127 related articles for article (PubMed ID: 1768677)
1. Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
Bukowski RM; Sergi JS; Budd GT; Murthy S; Tubbs R; Gibson V; Bauer L; Stanley J; Gautam S; Finke J
J Immunother (1991); 1991 Dec; 10(6):432-9. PubMed ID: 1768677
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
6. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
Truitt RL; Piaskowski V; Kirchner P; McOlash L; Camitta BM; Casper JT
J Immunother (1991); 1992 May; 11(4):274-85. PubMed ID: 1599913
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study.
Pais RC; Abdel-Mageed A; Ghim TT; Ode D; Melendez E; Kim HS; Findley H; Ragab AH
J Immunother (1991); 1992 Aug; 12(2):138-46. PubMed ID: 1504055
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
10. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
11. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
[TBL] [Abstract][Full Text] [Related]
12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
13. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
[TBL] [Abstract][Full Text] [Related]
15. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
17. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
[TBL] [Abstract][Full Text] [Related]
18. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Tauer KW; Orr DW; Barth NM; Blumenschein G; Arnold J; Birch R; West WH
J Clin Oncol; 1991 Jul; 9(7):1233-40. PubMed ID: 2045864
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
